European Primary Care Cardiovascular Society
Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?
Low gestational age at birth (<37 weeks) was associated with an increased risk for the development of HF into adulthood. The lower the gestational age of an infant at birth, the higher the risk for new-onset HF.
In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.
MI patients with atypical symptoms had a lower chance of receiving an emergency dispatch, and higher 30-day mortality compared to MI patients with chest pain. Breathing problems was the most common atypical symptom.
Experts in dialogue Is the case for LDL-c lowering sufficiently proven or is there a need for more studies? Prof. Ray and prof. Kastelein talk about this topic and exchange their views on LDL-c lowering.
This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.
Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.
Prof. Steffel presents a subanalysis of the ENGAGE AF-TIMI 48 trial that compared lower dose edoxaban vs. approved higher dose edoxaban regimens for (net) clinical outcomes in patients with AF.
A meta-analysis of 5 trials showed that colchicine reduced MACE by 25% compared to placebo or no colchicine with a low between-trial heterogeneity in a wide range of patients with coronary disease.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
This 1 year follow-up study of patients with HF in a real-world setting showed that hospital readmissions frequently occurred during the first 3 months after discharge and were mainly caused by worsening HF and a higher number of co-morbidities.
Lower dose edoxaban regimen decreased the net clinical outcome of major bleeding, stroke/systemic embolism, and death compared to higher dose edoxaban regimen in patients with AF.